Breakthrough reactions in pediatric chemotherapeutic desensitization: Outcomes and associated risk factors
Pediatric Allergy and Immunology · 2026
DOI: 10.1111/pai.70425 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Pediatric Allergy and Immunology, 2026. Verfasst von Pathitta Doradee und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Allergy and Immunology, Department of Pediatrics, Faculty of Medicine, Siriraj Hospital Mahidol University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Desensitization, Immunologic, Drug Hypersensitivity, Antineoplastic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Rapid drug desensitization (RDD) enables the safe reintroduction of chemotherapeutic agents in patients with hypersensitivity reactions (HSRs). However, some patients experience breakthrough reactions (BTRs) during desensitization, and research on factors associated with BTRs is limited in pediatric patients.
Methods
We conducted an ambispective observational cross‐sectional study in Bangkok, Thailand. Patients ≤18‐year‐old who experienced immediate HSRs (within 1–6 h) to chemotherapeutic agents and underwent RDD following evaluation by allergists between January 2010 and April 2025 were included.
Results
A total of 182 RDDs were performed in 38 children (median age of 5.3 years). The majority were diagnosed with acute leukemia (47.4%), and the most common causative agents for HSRs were E. coli ‐Asparaginase (26.9%), vincristine (24.7%), and methotrexate (13.7%). Asparaginase, vincristine, cyclophosphamide, carboplatin/oxaliplatin, and doxorubicin were commonly associated with Type I HSRs, while methotrexate, cyclosporin A and etoposide were linked to Type I HSRs as well as infusion‐related reactions (IRRs) or cytokine‐release reactions (CRRs). Twenty‐nine BTRs occurred during RDD (15.9%), most of which were mild (72.4%). Independent risk factors for BTRs included E. coli ‐Asparaginase desensitization (adjusted OR 3.87 [1.45, 10.39], p = .007), and a higher initial starting dose (ratio ≤1:10,000) (adjusted OR 3.51 [1.02, 12.18], p = .048). Conversely, later cycles of desensitization reduced the risk of BTRs (adjusted OR 0.47 [0.31, 0.72], p < .001).
Conclusion
RDDs for chemotherapeutic agents effectively enable safe treatment continuation in most children with immediate HSRs, including type I HSR, CRR, and mixed reactions. In our study, E. coli ‐Asparaginase, a higher initial starting dose, and an early desensitization cycle were identified as having potential risk factors associated with BTRs. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Allergy and Immunology, Department of Pediatrics, Faculty of Medicine, Siriraj Hospital Mahidol University, Bangkok, Thailand.
- Department of Clinical Epidemiology, Faculty of Medicine, Thammasat University, Pathum Thani, Thailand.
- Division of Allergy and Immunology, Department of Pediatrics, Faculty of Medicine, Thammasat University, Pathum Thani, Thailand.
ORCID-Profile: Witchaya Srisuwatchari
Zitieren
APA
Doradee, P., Tangvalelerd, S., Kanchanapoomi, K., Kulalert, P., Pacharn, P., Jirapongsananuruk, O., & Srisuwatchari, W. (2026). Breakthrough reactions in pediatric chemotherapeutic desensitization: Outcomes and associated risk factors. Pediatric Allergy and Immunology. https://doi.org/10.1111/pai.70425
Vancouver
Doradee P, Tangvalelerd S, Kanchanapoomi K, Kulalert P, Pacharn P, Jirapongsananuruk O, et al. Breakthrough reactions in pediatric chemotherapeutic desensitization: Outcomes and associated risk factors. Pediatric Allergy and Immunology. 2026. doi:10.1111/pai.70425
BibTeX
@article{Doradee2026,
author = {Doradee, Pathitta and Tangvalelerd, Supaluk and Kanchanapoomi, Kantima and Kulalert, Prapasri and Pacharn, Punchama and Jirapongsananuruk, Orathai and Srisuwatchari, Witchaya},
title = {Breakthrough reactions in pediatric chemotherapeutic desensitization: Outcomes and associated risk factors},
journal = {Pediatric Allergy and Immunology},
year = {2026},
doi = {10.1111/pai.70425}
}
EUVIMED